Nearly half the world cannot reliably access quality diagnostics. In India the gap is not about money alone — it is structural. Here is why, and why incremental fixes will not close it.
A gap measured in hundreds of millions
The World Health Organization estimates that roughly 47% of the global population has little or no access to quality diagnostics. In India, the consequence is concentrated in the 800 million people living outside major urban centres — where more than 60% of primary health centres have no laboratory capability beyond basic rapid tests.
This matters because an estimated 80% of clinical decisions depend on a diagnostic result. Where testing is absent, medicine becomes guesswork: chronic disease is caught late, infections are treated empirically, and outbreaks are detected only once they are already widespread.
Why it is a design problem, not a budget problem
The instinctive response is to build more central laboratories. But the architecture of conventional diagnostics — cold-chain reagents, accredited labs, trained pathologists, and institutional procurement — creates a barrier that grows with every kilometre from a major city. Adding more of the same infrastructure does not reach the places that infrastructure was never designed to serve.
The wealthier segments of India suffer from the same late-diagnosed non-communicable diseases as everyone else, which tells us the problem is not purely financial. It is a system designed around acute response rather than continuous, accessible measurement.
The case for building differently
BIQADX starts from a different set of assumptions: minimal reagent dependency, rugged hardware, AI-assisted interpretation, and affordability designed in from the first principle rather than discounted in at the end. The goal is not a cheaper version of the existing model — it is a different model entirely, built for the conditions where most people actually live.